英文药名：Elcitonin Inj.20S（Elcatonin[r-INN]）

中文药名：依降钙素（r-INN）注射剂

生产厂家：旭化成制药

エルシトニン注20S

治疗类别名称
骨质疏松症治疗剂
商標名
Elcitonin Inj.20S
一般名
エルカトニン（JAN）
Elcatonin（r-INN）
構造式

分子式
C148H244N42O47
分子量
3363.77
性状
本品是一种白色粉末。
它是易溶于水，易溶于乙醇（95），并在乙腈中几乎不溶。
本产品是吸湿。
此产品（1→500）的水溶液的pH值是从4.5到7.0。
条件批准
它被迅速地进行临床试验，以确认在日本患者骨质疏松这种药物的骨折抑制效果。
药效药理
1. 抗伤害效果（镇痛作用）
依降钙素的反复皮下注射，它承认对福尔马林引起痛觉过敏和卵巢切除导致的痛觉过敏的抗伤害性作用（镇痛作用），通过揭示羟色胺神经系统的疼痛抑制系统的机制和（鼠）。
此外，依降钙素承认指示血流中的肌肉萎缩和外围减少血流改善对神经性疼痛模型（坐骨神经结扎大鼠）动作和抗感受伤害作用（镇痛作用）。
2. 对实验性骨质疏松的作用
依降钙素，在低钙饮食和泼尼松龙的治疗，以及实验性骨质疏松动物已被诱导卵巢切除（大鼠，狗），骨强度，骨皮质宽度，骨密度，骨的钙含量，尿中羟脯氨酸的排泄量被调查作为指标的结果，也承认其预防效果。
3. 骨吸收抑制作用
依降钙素抑制正常动物（大鼠，狗）及实验性骨质疏松动物（大鼠，狗）的骨吸收作用。此外，在大鼠和小鼠，抑制从骨中的钙释放与各种骨吸收促进因子的骨培养系统（体外）。
4. 骨形成促进作用
依降钙素，在大鼠骨培养系统中，已经发现，以促进一剂量依赖性骨形成和骨矿化（体外）。另外，在狗，已经发现，以促进骨形成。
适应病症
疼痛骨质疏松症
用法与用量
20依降钙素单元的肌内注射，每周一次。
包装规格
注射液
20S单位/1毫升/安瓿：10S安瓿

制造厂商
旭化成制药株式会社
完整处方资料附件（以上中文资料仅供参考，使用请以原处方资料为准）：http://www.info.pmda.go.jp/go/pack/3999401A3024_2_12/

Elcitonin Inj.20S（Elcatonin）
Brand name : Elcitonin Inj.20S
　Active ingredient: Elcatonin
　Dosage form: injection
　Print on wrapping: 
Effects of this medicine
This medicine is a synthetic calcitonin preparation. Calcitonin is a hormone involved with bone metabolism. This medicine suppresses bone resorption (breaking bone down). It also acts on the pain suppressing nerve system.
It is usually used for pain due to osteoporosis.
Before using this medicine, be sure to tell your doctor and pharmacist
•If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
•If you are pregnant or breastfeeding.
•If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
Dosing schedule (How to take this medicine)
•Your dosing schedule prescribed by your doctor is <<to be written by a healthcare professional>>
•In general, for adults, this medicine is injected intramuscularly once a week.
The treatment period with this medicine depends on your symptoms. However, the standard treatment period is 6 months.
Precautions while taking this medicine
• Possible adverse reactions to this medicine
The most commonly reported adverse reactions include nausea, hot flush (facial glow/redness), rash and hives. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
•general redness (skin red rash), hives, respiratory distress [shock, anaphylactoid symptoms]
•numbness, convulsion [tetany]
•convulsive shortness of breath, wheezing (whistling breath) [asthma attack]
•general malaise, loss of appetite, yellowing of the skin and the white of eyes [liver dysfunction, jaundice]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
Asahi Kasei Pharma CorporationInjection
Published: 7/2016
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.